ABIGAIL ASUMADU-MENSAH: Open Payments
NPI 1063163020 · ALEXANDRIA, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$212 in 11 payments from 9 companies in 2025. Trend: 2023 $234 · 2024 $352 · 2025 $212
Food & beverage: $212
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 3 | $58 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $29 |
| Verona Pharma, Inc. | 1 | $22 |
| Xeris Pharmaceuticals, Inc. | 1 | $22 |
| AstraZeneca Pharmaceuticals LP | 1 | $20 |
| Axsome Therapeutics, Inc. | 1 | $17 |
| Corcept Therapeutics | 1 | $16 |
| Paratek Pharmaceuticals, Inc. | 1 | $14 |
| Amgen Inc. | 1 | $14 |
Products named: VRAYLAR, CAPLYTA, Ohtuvayre, GVOKE HYPOPEN, AIRSUPRA, Auvelity, QULIPTA, Korlym.
Industry payments across VA — which companies pay providers there.
